| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
BridgeBio Oncology Therapeutics, Inc.
13D/A
BBOT · 107924102
|
22.6% |
8/13/2025
Event 8/11/2025
|
||||
| Helix Holdings II LLC | 5.7% | |||||
| Cormorant Global Healthcare Master Fund, LP | 7.5% | |||||
| Cormorant Global Healthcare GP, LLC | 7.5% | |||||
| Bihua Chen | 22.6% | |||||
|
Helix Acquisition Corp. II
13D/A
HLXB · G4444H101
|
31.6% |
3/4/2025
Event 2/28/2025
|
||||
| Helix Holdings II LLC | 21.3% | |||||
| Cormorant Private Healthcare Fund III, LP | 7.6% | |||||
| Cormorant Private Healthcare GP III, LLC | 7.6% | |||||
| Bihua Chen | 31.6% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.